NCT03853616 - MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Acute Lymphoblastic Leukemia RecurrentB-cell Lymphoma RecurrentB-cell Lymphoma RefractoryChronic Lymphocytic Leukemia RecurrentChronic Lymphocytic Leukemia Refractory

Interventions

BIOLOGICAL

MB-CART19.1

MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies

Trial Locations (9)

13353

Charité - University clinic, pediatric clinic with focus on oncology and hematology, Berlin

37075

University medicine Goettingen, Clinic of hematology and medical oncology, Göttingen

48149

Universitätsklinikum Münster - Klink für Kinderheilkunde und Jugendmedizin / Pädiatrische Hämatologie und Onkologie, Münster

Universitätsklinikum Münster - Medizinische Klinik A / KMT Zentrum, Münster

72076

Tuebingen University clinic, medical university clinic for internal medicine, Tübingen

University clinic for children and youth medicine, Tübingen

80337

Children's Hospital of Dr. von Hauner by Ludwig-Maximilian University, Munich

91054

Universitätsklinikum Erlangen, Erlangen

97070

University clinic, pediatric hematology and oncology, Würzburg